The agency's new rules would clarify its process on granting "waivers" that allow experts with financial ties to drug firms to serve on approval boards. Under the new rules, experts who had been paid by a pharmaceutical company's marketing department would be barred from serving on advisory committees, but experts with other, less obvious financial ties to drug companies -- such as university grants or paid research -- would still be allowed to serve on such committees.
"There are very few academic experts engaged in research who don't have some ties to the industry," says Dr. Scott Gottlieb, FDA deputy commissioner for medical and scientific affairs.
However, critics of the FDA say there are plenty of medical experts who are free from the taint of drug company money. "The idea that all the bright people in the medical world are working for industry is just not right," says Merrill Goozner, director of the Integrity in Science Project at the Center for Science in the Public Interest.
While the FDA's new rules are supposed to bring transparency to the waiver process, critics argue that there should not be waivers at all, and that medical experts should not have any financial ties to the drug industry -- no matter how small or how far in the past. They say any level of involvement can taint the advisory committee votes that greatly influence drug company stock prices.
Representative Maurce D. Hinchey, D-NY, sponsored legislation last year to bar the FDA from allowing anyone with any industry ties from serving on advisory boards. The legislation passed the House but has yet to pass the Senate.
While the FDA argues that it must allow waivers because ostensibly the most competent experts all have industry ties, critics maintain that the FDA cannot properly supervise such a process, since in the past it has made decisions that favored the interests of drug companies over public safety. FDA critic Mike Adams had this to say: "That the FDA has announced it will slightly reduce the level of corruption it allows in drug decision boards is yet another example of this agency's utter lack of integrity. Allowing the FDA to restructure its blatant conflicts of interests is akin to handing over the asylum keys to the inmates."
###
 |
Additional Resources:
the FDA
conflicts of interest
drug racket
|
Take Action: Support NaturalNews.com
Email this article to a friend
Share this article on: NewsVine | digg | del.icio.us
Permalink to this article: http://www.NaturalNews.com/019744.html
Reprinting this article: Non-commercial OK, cite NaturalNews.com with clickable link.
|
 |
 |
Receive our Natural Health Newsletter for FREE
Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber!
- Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more.
- Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.
|
|
 |
 |
Recommended Special Report:
Seven Words that can Change the World
by Joseph R. Simonetta
Read this special report now...
"Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com
|
More on NaturalNews.com:
• Streaming Health Ranger Videos
• CounterThink Cartoons
• FREE Special Reports
• Podcasts
|
 |